OPEN END TURBO LONG - HALEON Stock

Certificat

DE000MD7LM32

Market Closed - Börse Stuttgart 10:03:27 2024-05-24 am EDT
0.64 EUR -11.11% Intraday chart for OPEN END TURBO LONG - HALEON
Current month-17.95%
1 month-4.48%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
24-05-24 0.64 -11.11%
24-05-23 0.72 +5.88%
24-05-22 0.68 -4.23%
24-05-21 0.71 -4.05%
24-05-20 0.74 +5.71%

Delayed Quote Börse Stuttgart

Last update May 24, 2024 at 10:03 am EDT

More quotes

Static data

Product typeKnock-Out ohne Stop Loss
Buy / SellCALL
Underlying HALEON PLC
Issuer Morgan Stanley
WKN MD7LM3
ISINDE000MD7LM32
Date issued 2022-08-30
Strike 271.3 p
Maturity Unlimited
Parity 1 : 1
Emission price 0.32
Emission volume N/A
Settlement Barausgleich
Currency EUR

Technical Indicators

Highest since issue 1.21
Lowest since issue 0.039

Company Profile

Haleon plc specializes in the research, manufacture and marketing of drugs and consumer pharmaceutical products. Net sales break down by family of products as follows: - oral health products (27.7%; no. 1 worldwide): Sensodyne, Parodontax, Polident, Biotene, Aquafresh brands, etc.; - Pain relief medicines (23.5%; no. 1 worldwide): Panadol, Advil, Voltaren, Excedrin brands, etc.; - medicines for digestive health (18.9%; no. 1 worldwide): TUMS, Nicorette, ENO, Chap Stick, Fenistil, Nexium brands, etc.; - respiratory medicines (15.4%; no. 1 worldwide): Theraflu, Otrivin, Flonase, Contac brands, etc.; - vitamins, minerals and food supplements (14.5%; no. 1 worldwide): Centrum, Emergen-C, Caltrate brands, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa/Latin America (40.2%), North America (37.1%), and Asia/Pacific (22.7%).
Sector
-
More about the company

Ratings for Haleon plc

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Consensus: Haleon plc

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
3.23 GBP
Average target price
3.62 GBP
Spread / Average Target
+12.07%
Consensus